scorecardresearchNatco Pharma Share Price Live NSE, BSE, Today - Natco Pharma Stock Price
Mintgenie
Asian Paints3,180.40-30.35 (-0.95%)
Axis Bank974.4512.00 (1.25%)
Bajaj Finance7,036.4528.75 (0.41%)
Bajaj Finserve1,466.05-1.35 (-0.09%)
Bharti Airtel832.70-3.00 (-0.36%)
HCL Technologies1,110.30-16.70 (-1.48%)
HDFC Bank1,610.551.65 (0.10%)
Hindustan Unilever2,635.70-44.15 (-1.65%)
Housing Development Finance Corporation2,651.95-3.40 (-0.13%)
ICICI Bank939.652.35 (0.25%)
ITC438.45-4.40 (-0.99%)
Indusind Bank1,331.0027.65 (2.12%)
Infosys1,266.00-17.10 (-1.33%)
Kotak Mahindra Bank1,871.90-14.45 (-0.77%)
Larsen & Toubro2,363.9023.30 (1.00%)
Mahindra & Mahindra1,369.20-11.35 (-0.82%)
Maruti Suzuki India9,630.05-24.80 (-0.26%)
NTPC182.700.65 (0.36%)
Nestle India22,100.00-37.50 (-0.17%)
Power Grid Corporation Of India243.852.25 (0.93%)
Reliance Industries2,481.90-17.90 (-0.72%)
State Bank Of India578.60-9.90 (-1.68%)
Sun Pharmaceutical Industries983.15-3.95 (-0.40%)
Tata Consultancy Services3,210.45-25.70 (-0.79%)
Tata Motors562.202.55 (0.46%)
Tata Steel108.90-2.20 (-1.98%)
Tech Mahindra1,064.80-6.60 (-0.62%)
Titan Company2,876.850.05 00.000
Ultratech Cement8,153.9057.45 (0.71%)
Wipro397.85-1.65 (-0.41%)

Natco Pharma

BSE: 524816 | NSE: NATCOPHARM | ISIN: INE987B01026 | SECTOR: Biotechnology & Drugs

₹624.90 2.20 (0.35%)

09 Jun 2023, 09:59 (IST)

  • Open

    616.05

  • High

    625.05

  • Low

    616.05

  • Prev Close

    622.70

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    111.93B

  • Volume

    5.32K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    -

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    524816

  • NSE

    NATCOPHARM

  • ISIN

    INE987B01026

Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.

Company Officers

  • Rajeev Nannapaneni

    Chief Executive Officer, Executive Director

  • S. V. V. N. Appa Rao

    Chief Financial Officer

  • Lingarao Donthineni

    President - Technical Affairs, Executive Director

  • Pavan Bhat

    Executive Vice President - Technical Operations, Executive Director

  • Potluri Prasad

    Executive Vice President - Corporate Engineering Services, Executive Director

  • Rajesh Chebiyam

    Executive Vice President - Crop Health Sciences

  • Ramesh Dandala

    Executive Vice President - Technology Transfer, Intellectual Property Rights and Regulatory Affairs (API)

  • M. Pullam Reddy

    Executive Vice President - R&D

  • Sanivarapu Reddy

    Senior Vice President

  • Gopalakrishnan Vaidyanathan

    Senior Vice President - Analytical Research & Development